Jim Simons Indaptus Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 28,500 shares of INDP stock, worth $204,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,500

Previous 27,700 2.89%

Holding current value

$204,345

Previous $23,000 34.78%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$0.55 - $0.98 $440 - $784	800 Added 2.89%	28,500 $15,000
Q4 2024 Feb 13, 2025	BUY	$0.84 - $1.77 $504 - $1,062	600 Added 2.21%	27,700 $23,000
Q3 2024 Nov 13, 2024	BUY	$1.13 - $2.25 $565 - $1,125	500 Added 1.88%	27,100 $33,000
Q2 2024 Aug 09, 2024	BUY	$2.0 - $2.8 $1,000 - $1,400	500 Added 1.92%	26,600 $56,000
Q1 2024 May 13, 2024	SELL	$1.63 - $2.8 $5,379 - $9,240	-3,300 Reduced 11.22%	26,100 $58,000
Q4 2023 Feb 13, 2024	BUY	$1.75 - $2.75 $8,750 - $13,750	5,000 Added 20.49%	29,400 $52,000
Q3 2023 Nov 14, 2023	BUY	$1.75 - $3.95 $6,300 - $14,220	3,600 Added 17.31%	24,400 $67,000
Q2 2023 Aug 11, 2023	BUY	$1.6 - $3.04 $2,560 - $4,864	1,600 Added 8.33%	20,800 $40,000
Q1 2023 May 12, 2023	BUY	$1.51 - $1.9 $151 - $190	100 Added 0.52%	19,200 $36,000
Q4 2022 Feb 13, 2023	SELL	$1.37 - $2.19 $822 - $1,314	-600 Reduced 3.05%	19,100 $28,000
Q3 2022 Nov 14, 2022	BUY	$2.16 - $3.33 $216 - $333	100 Added 0.51%	19,700 $43,000
Q2 2022 Aug 12, 2022	BUY	$1.94 - $4.02 $38,024 - $78,791	19,600 New	19,600 $51,000

Others Institutions Holding INDP

# of Institutions

Shares Held

243K

Call Options Held

Put Options Held

View Full List

About Indaptus Therapeutics, Inc.

Ticker INDP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,258,600
Market Cap $59.2M
Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...

More about INDP

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account